470 related articles for article (PubMed ID: 29181702)
21. Long-term survival and impact of ursodeoxycholic acid treatment for recurrent primary biliary cirrhosis after liver transplantation.
Charatcharoenwitthaya P; Pimentel S; Talwalkar JA; Enders FT; Lindor KD; Krom RA; Wiesner RH
Liver Transpl; 2007 Sep; 13(9):1236-45. PubMed ID: 17763401
[TBL] [Abstract][Full Text] [Related]
22. How the concept of biochemical response influenced the management of primary biliary cholangitis over time.
Lammers WJ; Leeman M; Ponsioen CI; Boonstra K; van Erpecum KJ; Wolfhagen FH; Kuyvenhoven JP; Vrolijk JM; Drenth JP; Witteman EM; van Nieuwkerk CM; van der Spek BW; Witteman BJ; Erkelens GW; Verhagen MA; van Tuyl SA; Poen AC; Brouwer JT; Ter Borg F; Koek GH; van Ditzhuijsen TJ; Hansen BE;
Neth J Med; 2016 Jul; 74(6):240-6. PubMed ID: 27571721
[TBL] [Abstract][Full Text] [Related]
23. Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis.
Tanaka A; Hirohara J; Nakano T; Matsumoto K; Chazouillères O; Takikawa H; Hansen BE; Carrat F; Corpechot C
J Hepatol; 2021 Sep; 75(3):565-571. PubMed ID: 33882268
[TBL] [Abstract][Full Text] [Related]
24. Epidemiology and clinical course of primary biliary cholangitis in Eastern Slovakia.
Drazilova S; Babinska I; Gazda J; Halanova M; Janicko M; Kucinsky B; Safcak D; Martinkova D; Tarbajova L; Cekanova A; Jarcuska P;
Int J Public Health; 2020 Jun; 65(5):683-691. PubMed ID: 32500239
[TBL] [Abstract][Full Text] [Related]
25. Rate of non-response to ursodeoxycholic acid in a large real-world cohort of primary biliary cholangitis patients in Italy.
Vespasiani-Gentilucci U; Rosina F; Pace-Palitti V; Sacco R; Pellicelli A; Chessa L; De Vincentis A; Barlattani M; Barlattani A; Feletti V; Mussetto A; Zolfino T; Russello M; Cozzolongo R; Garrucciu G; Niro G; Bacca D; Bertino G; Claar E; Ascione A; D'Adamo G; Adinolfi LE; Scifo G; Izzi A;
Scand J Gastroenterol; 2019 Oct; 54(10):1274-1282. PubMed ID: 31564176
[No Abstract] [Full Text] [Related]
26. Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis.
Gatselis NK; Goet JC; Zachou K; Lammers WJ; Janssen HLA; Hirschfield G; Corpechot C; Lindor KD; Invernizzi P; Mayo MJ; Battezzati PM; Floreani A; Pares A; Lygoura V; Nevens F; Mason AL; Kowdley KV; Ponsioen CY; Bruns T; Thorburn D; Verhelst X; Harms MH; van Buuren HR; Hansen BE; Dalekos GN;
Clin Gastroenterol Hepatol; 2020 Mar; 18(3):684-692.e6. PubMed ID: 31419573
[TBL] [Abstract][Full Text] [Related]
27. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.
Kuiper EM; Hansen BE; de Vries RA; den Ouden-Muller JW; van Ditzhuijsen TJ; Haagsma EB; Houben MH; Witteman BJ; van Erpecum KJ; van Buuren HR;
Gastroenterology; 2009 Apr; 136(4):1281-7. PubMed ID: 19208346
[TBL] [Abstract][Full Text] [Related]
28. Ursodeoxycholic Acid Treatment-Induced GLOBE Score Changes Are Associated With Liver Transplantation-Free Survival in Patients With Primary Biliary Cholangitis.
de Veer RC; van Hooff MC; Corpechot C; Thorburn D; Invernizzi P; Lammers WJ; Janssen HLA; Battezzati PM; Nevens F; Lindor KD; Floreani A; Ponsioen CY; Mayo MJ; Parés A; Mason AL; Kowdley KV; Trivedi PJ; Hirschfield GM; Goet JC; Bruns T; Dalekos GN; Gatselis NK; Verhelst X; Hansen BE; Harms MH; van der Meer AJ;
Am J Gastroenterol; 2023 Jul; 118(7):1196-1203. PubMed ID: 36621963
[TBL] [Abstract][Full Text] [Related]
29. Emerging drugs for the treatment of Primary Biliary Cholangitis.
Ali AH; Tabibian JH; Carey EJ; Lindor KD
Expert Opin Emerg Drugs; 2016; 21(1):39-56. PubMed ID: 26901615
[TBL] [Abstract][Full Text] [Related]
30. Anti-Mitochondrial Antibody Titers Decrease Over Time in Primary Biliary Cholangitis Patients With Ursodeoxycholic Acid Therapeutic Response: A Cohort Study Followed Up to 28 Years.
Chang ML; Chen WT; Chan TM; Lin CY; Chang MY; Chen SC; Chien RN
Front Immunol; 2022; 13():869018. PubMed ID: 35663951
[TBL] [Abstract][Full Text] [Related]
31. Analysis of predictive response scores to treatment with ursodeoxycholic acid in patients with primary biliary cholangitis.
Brunet E; Hernández L; Miquel M; Sánchez-Delgado J; Dalmau B; Valero O; Vergara M; Casas M
Med Clin (Barc); 2019 May; 152(10):377-383. PubMed ID: 30297252
[TBL] [Abstract][Full Text] [Related]
32. Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group.
Poupon RE; Bonnand AM; Chrétien Y; Poupon R
Hepatology; 1999 Jun; 29(6):1668-71. PubMed ID: 10347106
[TBL] [Abstract][Full Text] [Related]
33. The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis.
Carbone M; Sharp SJ; Flack S; Paximadas D; Spiess K; Adgey C; Griffiths L; Lim R; Trembling P; Williamson K; Wareham NJ; Aldersley M; Bathgate A; Burroughs AK; Heneghan MA; Neuberger JM; Thorburn D; Hirschfield GM; Cordell HJ; Alexander GJ; Jones DE; Sandford RN; Mells GF;
Hepatology; 2016 Mar; 63(3):930-50. PubMed ID: 26223498
[TBL] [Abstract][Full Text] [Related]
34. Does antimitochondrial antibody status affect response to treatment in patients with primary biliary cirrhosis? Outcomes of ursodeoxycholic acid therapy and liver transplantation.
Kim WR; Poterucha JJ; Jorgensen RA; Batts KP; Homburger HA; Dickson ER; Krom RA; Wiesner RH; Lindor KD
Hepatology; 1997 Jul; 26(1):22-6. PubMed ID: 9214447
[TBL] [Abstract][Full Text] [Related]
35. Predictive scores in primary biliary cirrhosis: a retrospective single center analysis of 204 patients.
Weinmann A; Sattler T; Unold HP; Grambihler A; Teufel A; Koch S; Schuchmann M; Biesterfeld S; Wörns MA; Galle PR; Schulze-Bergkamen H
J Clin Gastroenterol; 2015; 49(5):438-47. PubMed ID: 25014239
[TBL] [Abstract][Full Text] [Related]
36. IgM response is a prognostic biomarker of primary biliary cholangitis treated with ursodeoxycholic acid and bezafibrate.
Takano K; Saeki C; Oikawa T; Hidaka A; Mizuno Y; Ishida J; Takakura K; Nakano M; Torisu Y; Amano K; Ishikawa T; Zeniya M; Tsubota A; Saruta M
J Gastroenterol Hepatol; 2020 Apr; 35(4):663-672. PubMed ID: 31677185
[TBL] [Abstract][Full Text] [Related]
37. A validated clinical tool for the prediction of varices in PBC: the Newcastle Varices in PBC Score.
Patanwala I; McMeekin P; Walters R; Mells G; Alexander G; Newton J; Shah H; Coltescu C; Hirschfield GM; Hudson M; Jones D
J Hepatol; 2013 Aug; 59(2):327-35. PubMed ID: 23608623
[TBL] [Abstract][Full Text] [Related]
38. Liver transplant-free survival according to alkaline phosphatase and GLOBE score in patients with primary biliary cholangitis treated with ursodeoxycholic acid.
de Veer RC; Harms MH; Corpechot C; Thorburn D; Invernizzi P; Janssen HLA; Battezzati PM; Nevens F; Lindor KD; Floreani A; Ponsioen CY; Mayo MJ; Parés A; Mason AL; Kowdley KV; Trivedi PJ; Hirschfield GM; Bruns T; Dalekos GN; Gatselis NK; Verhelst X; Lammers WJ; Hansen BE; van Buuren HR; van der Meer AJ;
Aliment Pharmacol Ther; 2022 Nov; 56(9):1408-1418. PubMed ID: 36138566
[TBL] [Abstract][Full Text] [Related]
39. Factors Associated With Prevalence and Treatment of Primary Biliary Cholangitis in United States Health Systems.
Lu M; Li J; Haller IV; Romanelli RJ; VanWormer JJ; Rodriguez CV; Raebel MA; Boscarino JA; Schmidt MA; Daida YG; Sahota A; Vincent J; Bowlus CL; Lindor K; Rupp LB; Gordon SC;
Clin Gastroenterol Hepatol; 2018 Aug; 16(8):1333-1341.e6. PubMed ID: 29066370
[TBL] [Abstract][Full Text] [Related]
40. Pruritus Is Common and Undertreated in Patients With Primary Biliary Cholangitis in the United Kingdom.
Hegade VS; Mells GF; Fisher H; Kendrick S; DiBello J; Gilchrist K; Alexander GJ; Hirschfield GM; Sandford RN; Jones DEJ;
Clin Gastroenterol Hepatol; 2019 Jun; 17(7):1379-1387.e3. PubMed ID: 30557739
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
